BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale
- Supplementary File 1:
PDF-Document (PDF, 228 KiB)
Bracht, J.W.P.; Karachaliou, N.; Bivona, T.; Lanman, R.B.; Faull, I.; Nagy, R.J.; Drozdowskyj, A.; Berenguer, J.; Fernandez-Bruno, M.; Molina-Vila, M.A.; Rosell, R. BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale. Cancers 2019, 11, 1381.
Bracht JWP, Karachaliou N, Bivona T, Lanman RB, Faull I, Nagy RJ, Drozdowskyj A, Berenguer J, Fernandez-Bruno M, Molina-Vila MA, Rosell R. BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale. Cancers. 2019; 11(9):1381.
Chicago/Turabian StyleBracht, Jillian W.P.; Karachaliou, Niki; Bivona, Trever; Lanman, Richard B.; Faull, Iris; Nagy, Rebecca J.; Drozdowskyj, Ana; Berenguer, Jordi; Fernandez-Bruno, Manuel; Molina-Vila, Miguel A.; Rosell, Rafael. 2019. "BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale" Cancers 11, no. 9: 1381.